Table 2.

Breakout of CD architecture

	Percent, %
Length of Lithium Treatment	AQP4+V-ATPase−	AQP4−V-ATPase+	AQP4+V-ATPase+	Cells/CDSection
Control	90.5 ± 0.565	9.50 ± 0.565	0.00 ± 0.00	6.05 ± 0.976
1 Week	90.7 ± 0.875	9.22 ± 0.871	0.0895 ± 0.0584	7.40 ± 0.700
2 Weeks	94.3 ± 0.744	4.91 ± 0.609	0.836 ± 0.177	7.07 ± 0.936
3 Weeks	89.9 ± 0.969	9.59 ± 1.31	0.513 ± 0.416	9.22 ± 0.936
6 Weeks	72.6 ± 4.89*	26.1 ± 5.09*	1.39 ± 0.275	9.04 ± 1.99
9 Weeks	56.8 ± 7.02*	43.1 ± 7.03*	0.108 ± 0.0560	8.74 ± 1.15
12 Weeks	57.8 ± 0.829*	41.4 ± 1.06*	0.829 ± 0.352	10.2 ± 1.30

Data are presented as percentages or number of cells per collecting duct and are expressed as mean proportion ± SE of the proportion. CD, collecting duct. With the use of mages collected from the terminal inner medullary (IM) region, cells that expressed only aquaporin-4 (AQP4), only vacuolar H⁺-ATPase (V-ATPase), or both AQP4 and V-ATPase were analyzed using the functionally equivalent “multipointer” or “cell counter” plugins in ImageJ software. Arcsine-transformed data were subjected to a Kruskal-Wallis one-way ANOVA and Tukey’s post hoc test.

^*P < 0.05 vs. control; n = 3 wk.